Integra Enrollment in Cadence Total Ankle Postmarket Study

Integra LifeSciences implanted the first Cadence® Total Ankle as part of a non-randomized, prospective, multi-center postmarket study.

The trial will evaluate 2-year implant survivorship, which will be further evaluated at 5 and 10 years post-op. All patients will receive the Cadence device.

Since initial clinical use in 2Q16, >350...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us